Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 5, 2004, Pages

  Altice, Frederick L ^a   Mezger, Jo Anne ^a   Hodges, John ^a   Bruce, Robert D ^a   Marinovich, Adrian ^a   Walton, Mary ^a   Springer, Sandra A ^a   Friedland, Gerald H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; METHADONE; VIRUS RNA;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; COMORBIDITY; CONFIDENTIALITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABUSE; DRUG SELF ADMINISTRATION; EMERGENCY WARD; ETHNIC GROUP; FEMALE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL EDUCATION; MEDICAL SERVICE; MEDICAL STAFF; METHADONE TREATMENT; PATIENT COMPLIANCE; PHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL ASPECT; SOCIAL SUPPORT; SUBSTANCE ABUSE; SYRINGE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; RNA, VIRAL; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 2942530602     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421400     Document Type: Article

References (89)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Ward JW, Duchin JS. The epidemiology of HIV and AIDS in the United States. AIDS Clin Rev 1997-98:1-45.
3. Centers for Disease Control and Prevention. Update: AIDS - United States, 2000. MMWR Morb Mortal Wkly Rep 2002; 51:592-5.
4. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22:369-78.
5. Goedert JJ, Fung MW, Felton S, et al. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001; 15:1295-302.
6. Whitman S, Murphy J, Cohen M, et al. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Arch Intern Med 2000; 160:365-9.
7. Page JB, Lai S, Fletcher MA, et al. Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users. Clin Diagn Lab Immunol 1996; 3:51-60.
8. Lucas GM, Gebo KM, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74.
9. Whitman S, Murphy J, Cohen M, et al. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Arch Intern Med 2000; 160:365-9.
10. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injecting drug users in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-23.
11. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effects of ongoing illicit drug user. Am J Drug Alcohol Abuse 2000; 26:195-205.
12. Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr 1999; 22:461-6.
13. Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J Acquir Immune Defic Syndr 2000; 23:178-83.
14. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-83.
15. Zaccarelli M, Barracchini A, De Longis P, et al. Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care STDs 2002; 16:67-73.
16. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-79.
17. Pillay D. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population. Antivir Ther 2001; 6(Suppl 3):15-24.
18. Paris D, Ledergerber B, Weber R, et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999; 15:1631-8.
19. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-11.
20. Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission of HIV-1 infection. Ann NY Acad Sci 2000; 918:9-15.
21. Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000; 61:181-6.
22. Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus - the wake-up call. N Engl J Med 1998; 339:341-3.
23. Heimer R Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abuse Treat 1998; 15:183-91.
24. Heimer R, Kaplan EH, O'Keefe E, Khoshnood K, Altice FL. Three years of needle exchange in New Haven: what have we learned? AIDS Public Policy J 1994; 9:59-74.
25. Shah NG, Celentano DD, Vlahov D, et al. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS 2000; 14:2035-43.
26. Riley ED, Vlahov D, Huettner S, et al. Characteristics of injection drug users who utilize tuberculosis services at sites of the Baltimore city needle exchange program. J Urban Health 2002; 79:113-27.
27. Liebman J, Pat Lamberti M, Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nurs 2002; 19:345-53.
28. Pollack HA, Khoshnood K, Blankenship KM, Altice FL. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med 2002; 17:341-8.
29. Des Jarlais DC, Fisher DG, Newman JC, et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health 2001; 91:1791-2.
30. Altice FL, Springer S, Buitrago M, et al. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 2003; 80:416-27.
31. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Reader 2002; 12:305-16.
32. Batki SL. Treatment of intravenous drug users with AIDS: the role of methadone maintenance. J Psychoactive Drugs 1988; 20:213-6.
33. Wall TL, Sorensen JL, Batki SL, et al. Adherence to zidovudine (AZT) among methadone maintenance patients: on-site dispensing compared to usual care. Drug Alcohol Depend 1995; 37:261-9.
34. Lucas GM, Weidle PJ, Hader S, et al. Directly administered antiretroviral therapy (DAART) in a methadone maintenance clinic improves HIV outcomes [abstract 489]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
35. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health 1999; 76:468-80.
36. Fischl M, Castro J, Monroig R, et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [abstract 528]. In: 8th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001.
37. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002; 34:511-8.
38. Wohl DA, Stephenson BL, Golin CE, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis 2003; 36:1572-6.
39. Stenzel MS, McKenzie M, Mitty JA, et al. Enhancing adherence to HAART: modified directly observed therapy. AIDS Reader 2001; 11:317-28.
40. Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002; 34:984-90.
41. Heymann SJ, Sell R, Brewer TF. The influence of program acceptability on the effectiveness of public health policy: a study of directly observed therapy for tuberculosis. Am J Public Health 1998; 88:442-5.
42. Curtis R, Friedman SR, Neaigus A, et al. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep 1994; 109:319-27.
43. Fujiwara PI, Larkin C, Frieden TR. Directly observed therapy in New York City. History, implementation, results, and challenges. Clin Chest Med 1997; 18:135-48.
44. Chaulk CP, Moore-Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945-51.
45. Centers for Disease Control and Prevention. Trends in AIDS incidence, death, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:165-73.
46. Connecticut Department of Public Health. HIV/AIDS Surveillance Report. Reported AIDS Cases 1995-2000. Available at: http://www.dph.state.ct.us/BCH/ infectiousdise/pdf/ Hiv_Aids%20Annual%20Report%202000.pdf. Accessed 16 July 2003.
47. Theall KP, Sterk CE, Elifson KW, et al. Factors associated with positive HIV serostatus among women who use drugs: continued evidence for expanding factors of influence. Public Health Rep 2003; 118:415-24.
48. Wilson T, DeHovitz JA. STDs, HIV, and crack cocaine: a review. AIDS Patient Care STDs 1997; 11:62-6.
49. Reynolds GL, Fisher DG, Wood MM, et al. Use of emergency room services by out-of-treatment drug users in Long Beach, California. J Addict Dis 2003; 22:1-13.
50. Metsch LR, Pereyra M, Brewer TH. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J Subst Abuse 2001; 13:155-67.
51. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74.
52. Altice FL, Springer S, Buitrago M, et al. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 2003; 80:416-27.
53. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:47-58.
54. Friedman LM, Furberg CD, De Mets DL. The randomization process. In: Fundamentals of clinical trials. 3rd ed. New York: Spinger-Verlag, 1998:chap 5.
55. Pocock SJ. Current issues in the design and interpretation of clinical trials. Br Med J 1985; 290:39-42.
56. Markson LE, Houchens R, Fanning TR, et al. Repeated emergency department use by HIV-infected persons: effect of clinic accessibility and expertise in HIV care. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:35-41.
57. Reguero W, Crane M. Project MotherCare: one hospital's response to the high perinatal death rate in New Haven, CT. Public Health Rep 1994; 109:647-52.
58. Barry M, Fleck E, Lentz S, et al. "Medicine on wheels": an opportunity for outreach and housestaff education. Conn Med 1994; 58:535-9.
59. Schymura MJ, Thompson WD, Grady KE. Two interventions to improve use of screening for breast cancer. Prog Clin Biol Res 1989; 293:135-49.
60. Kaplan EH, Heimer R. HIV prevalence among intravenous drug users: model-based estimates from New Haven's legal needle exchange. J Acquir Immune Defic Syndr 1992; 5:163-9.
61. Herek GM, Mitnick L, Burris S, et al. Workshop report: AIDS and stigma: a conceptual framework and research agenda. AIDS Public Policy J 1998; 13:36-47.
62. Liebman J, Pat Lamberti M, Altice F. Effectiveness of a mobile medical van in providing screening services for STDs and HIV. Public Health Nurs 2002; 19:345-53.
63. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:47-58.
64. Mostashari F, Riley E, Selwyn PA, et al. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:341-8.
65. Martini M, Parazzini F, Agnoletto V. Characteristics of doctor-patient relationship and implication on adherence to antiretroviral treatments. HIV Med 2001; 2:62-3.
66. Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002; 34:686-92.
67. Boyle BA. Efficacy and safety of once-daily antiretroviral therapy. AIDS Reader 2002; 12:90-2, 95-6, 109.
68. El-Sadr W, Medard F, Barthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health 1996; 86:1146-9.
69. Fisher JD. The IMB model of adherence. Presented at: 1st International Workshop on the Information-Motivation-Behavioral Skills Model, Naples, Italy, 2001.
70. Fisher JD, Fisher WA, Amico R. An information-motivation-behavior skills model of adherence to highly active antiretroviral therapy. Paper presented at: AIDS Impact: Biopsychosocial Aspects of HIV Infection, Fifth International Conference, Brighton, United Kingdom, July 8-11, 2001.
71. DiIorio C, Resnicow K, McDonnell M, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. J Assoc Nurses AIDS Care 2003; 14:52-62.
72. Miller WR, Yahne CE, Tonigan JS. Motivational interviewing in drug abuse services: a randomized trial. J Consult Clin Psychol 2003; 71:754-63.
73. Koren ME, Bartel JC, Corliss J. Interventions to improve patient appointments in an ambulatory care facility. J Ambulatory Care Manage 1994; 17:76-80.
74. Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S154-7.
75. Kitahata MM, Dillingham PW, Chaiyakunapruk N, et al. Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort. Clin Infect Dis 2003; 36:803-11.
76. Safren SA, Hendriksen ES, Desousa N, et al. Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care 2003; 15:787-93.
77. Perlman DC, Friedmann P, Horn L, et al. Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing. J Urban Health 2003; 80:428-37.
78. Xianyi C, Fengzeng Z, Hongjin D, et al. The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ 2002; 80:430-6.
79. Ruohonen RP, Goloubeva TM, Trnka L, et al. Implementation of the DOTS strategy for tuberculosis in the Leningrad Region, Russian Federation (1998-1999). Int J Tuberc Lung Dis 2002; 6:192-7.
80. Davidow AL, Marmor M, Alcabes P. Geographic diversity in tuberculosis trends and directly observed therapy, New York City, 1991 to 1994. Am J Respir Crit Care Med 1997; 156:1495-500.
81. Howard AA, et al. Genotypic resistance is less frequent in subject with poor adherence [abstract 460]. In: Proceedings of the 40th annual meeting of the Infectious Diseases Society of America (Chicago). 2002. Alexandria, VA: Infectious Diseases Society of America, 2002.
82. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-32.
83. Bangsberg DR, Hect FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-66.
84. Farmer P, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Semin Respir Infect 1991; 6:254-60.
85. McDonald RJ, Memon AM, Reichman LB. Successful supervised ambulatory management of tuberculosis treatment failures. Ann Intern Med 1982; 96:297-302.
86. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112:397-406.
87. Aerts A, de Haller R. DOTS and DOTS plus: what's in a name. Int J Tuberc Lung Dis 2001; 5:879-80.
88. Nardell EA. Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes. BMJ 2003; 327:164.
89. Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 2003; 326:574.